MX2020008916A - Anticuerpos anti cd6 para el tratamiento del asma grave. - Google Patents

Anticuerpos anti cd6 para el tratamiento del asma grave.

Info

Publication number
MX2020008916A
MX2020008916A MX2020008916A MX2020008916A MX2020008916A MX 2020008916 A MX2020008916 A MX 2020008916A MX 2020008916 A MX2020008916 A MX 2020008916A MX 2020008916 A MX2020008916 A MX 2020008916A MX 2020008916 A MX2020008916 A MX 2020008916A
Authority
MX
Mexico
Prior art keywords
antibodies
severe asthma
asthma
treating
treating severe
Prior art date
Application number
MX2020008916A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Connelly
Cherie Ng
Original Assignee
Equillium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equillium Inc filed Critical Equillium Inc
Publication of MX2020008916A publication Critical patent/MX2020008916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020008916A 2018-02-27 2019-02-27 Anticuerpos anti cd6 para el tratamiento del asma grave. MX2020008916A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636092P 2018-02-27 2018-02-27
PCT/US2019/019872 WO2019169015A1 (en) 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma

Publications (1)

Publication Number Publication Date
MX2020008916A true MX2020008916A (es) 2021-02-15

Family

ID=65724591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008916A MX2020008916A (es) 2018-02-27 2019-02-27 Anticuerpos anti cd6 para el tratamiento del asma grave.

Country Status (14)

Country Link
US (2) US20210380711A1 (cg-RX-API-DMAC7.html)
EP (1) EP3759140A1 (cg-RX-API-DMAC7.html)
JP (1) JP7572041B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200128415A (cg-RX-API-DMAC7.html)
CN (1) CN112424226B (cg-RX-API-DMAC7.html)
AU (1) AU2019228508A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017445A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091920A1 (cg-RX-API-DMAC7.html)
IL (1) IL276875A (cg-RX-API-DMAC7.html)
MX (1) MX2020008916A (cg-RX-API-DMAC7.html)
PH (1) PH12020551323A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008149RA (cg-RX-API-DMAC7.html)
WO (1) WO2019169015A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202005320B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
IL303290A (en) * 2020-12-04 2023-07-01 Equillium Inc Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AU747898B2 (en) 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
MY154819A (en) 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
CN102559636B (zh) * 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
JP6296650B2 (ja) 2013-03-13 2018-03-20 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用
TWI726897B (zh) 2015-07-15 2021-05-11 日商協和麒麟股份有限公司 與人類crth2特異性結合之抗體
US10562975B2 (en) 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce phosphorylation of cd6

Also Published As

Publication number Publication date
ZA202005320B (en) 2022-02-23
SG11202008149RA (en) 2020-09-29
EP3759140A1 (en) 2021-01-06
JP2021515039A (ja) 2021-06-17
BR112020017445A2 (pt) 2021-01-26
JP7572041B2 (ja) 2024-10-23
KR20200128415A (ko) 2020-11-12
CN112424226A (zh) 2021-02-26
IL276875A (en) 2020-10-29
US20210380711A1 (en) 2021-12-09
US20250034272A1 (en) 2025-01-30
CN112424226B (zh) 2025-03-14
RU2020130563A3 (cg-RX-API-DMAC7.html) 2022-04-01
PH12020551323A1 (en) 2021-04-26
CA3091920A1 (en) 2019-09-06
AU2019228508A1 (en) 2020-09-17
WO2019169015A1 (en) 2019-09-06
RU2020130563A (ru) 2022-03-28

Similar Documents

Publication Publication Date Title
PH12020551323A1 (en) Anti cd6 antibodies for treating severe asthma
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
CR20200467A (es) Agentes anticuerpos anti-cd25
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
PH12019502857A1 (en) Il-1 beta binding antibodies for use in treating cancer
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
MY205672A (en) Anti-phf-tau antibodies and uses thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
MX2019003338A (es) Tratamiento de cefalea en racimos.
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
PH12021553109A1 (en) Humanized antibody molecules to cd138 and uses thereof
MY186974A (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MX2020010092A (es) Variantes de anticuerpo c-terminales.
ZA202108422B (en) Anti-cd25 for tumour specific cell depletion